Christophe Pannecouque

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2995776/publications.pdf

Version: 2024-02-01

509 papers	16,778 citations	17440 63 h-index	39675 94 g-index
575 all docs	575 docs citations	575 times ranked	14335 citing authors

#	Article	IF	Citations
1	Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nature Protocols, 2008, 3, 427-434.	12.0	324
2	Synthesis and antiviral activity of new pyrazole and thiazole derivatives. European Journal of Medicinal Chemistry, 2009, 44, 3746-3753.	5.5	284
3	Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. Journal of Medicinal Chemistry, 2016, 59, 2849-2878.	6.4	260
4	Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Research, 2007, 75, 179-187.	4.1	242
5	Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure Prophylaxis. Antiviral Therapy, 2004, 9, 57-65.	1.0	228
6	Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1793-1796.	2.2	214
7	Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity. Journal of Medicinal Chemistry, 2015, 58, 9601-9614.	6.4	175
8	Synthesis and antiviral activity evaluation of some new 6-substituted 3-(1-adamantyl)-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles. Il Farmaco, 2002, 57, 253-257.	0.9	166
9	Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Bioorganic and Medicinal Chemistry, 2007, 15, 1725-1731.	3.0	164
10	Design, Synthesis, Structureâ˜'Activity Relationships, and Molecular Modeling Studies of 2,3-Diaryl-1,3-thiazolidin-4-ones as Potent Anti-HIV Agents. Journal of Medicinal Chemistry, 2002, 45, 5410-5413.	6.4	151
11	Chicoric Acid Analogues as HIV-1 Integrase Inhibitors. Journal of Medicinal Chemistry, 1999, 42, 1401-1414.	6.4	149
12	Polyanionic (i.e., Polysulfonate) Dendrimers Can Inhibit the Replication of Human Immunodeficiency Virus by Interfering with Both Virus Adsorption and Later Steps (Reverse Transcriptase/Integrase) in the Virus Replicative Cycle. Molecular Pharmacology, 2000, 58, 1100-1108.	2.3	149
13	Indolylarylsulfones as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: New Cyclic Substituents at Indole-2-carboxamide. Journal of Medicinal Chemistry, 2011, 54, 1587-1598.	6.4	137
14	Antiviral activity against human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) of ethnobotanically selected Ethiopian medicinal plants. Phytotherapy Research, 2001, 15, 62-69.	5.8	129
15	Improved and rapid synthesis of new coumarinyl chalcone derivatives and their antiviral activity. Tetrahedron Letters, 2007, 48, 8472-8474.	1.4	123
16	A 1,8-Naphthyridone Derivative Targets the HIV-1 Tat-Mediated Transcription and Potently Inhibits the HIV-1 Replication. Journal of Medicinal Chemistry, 2010, 53, 641-648.	6.4	122
17	Synthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin-4-one analogues as anti-HIV-1 agents. Bioorganic and Medicinal Chemistry, 2007, 15, 3134-3142.	3.0	119
18	Human Immunodeficiency Virus Glycoprotein gp120 as the Primary Target for the Antiviral Action of AR177 (Zintevir). Molecular Pharmacology, 1998, 53, 340-345.	2.3	118

#	Article	IF	Citations
19	Anti-HIV-1 activity of the G-quadruplex ligand BRACO-19. Journal of Antimicrobial Chemotherapy, 2014, 69, 3248-3258.	3.0	115
20	Deoxythreosyl Phosphonate Nucleosides as Selective Anti-HIV Agents. Journal of the American Chemical Society, 2005, 127, 5056-5065.	13.7	114
21	Bioactive Natural Products Prioritization Using Massive Multi-informational Molecular Networks. ACS Chemical Biology, 2017, 12, 2644-2651.	3.4	112
22	Graphene Quantum Dots Based Systems As HIV Inhibitors. Bioconjugate Chemistry, 2018, 29, 3084-3093.	3.6	111
23	Viral Entry as the Primary Target for the Anti-HIV Activity of Chicoric Acid and Its Tetra-Acetyl Esters. Molecular Pharmacology, 2000, 58, 641-648.	2.3	109
24	A time-ofâ€“drug addition approach to target identification of antiviral compounds. Nature Protocols, 2011, 6, 925-933.	12.0	108
25	Overview of Recent Strategic Advances in Medicinal Chemistry. Journal of Medicinal Chemistry, 2019, 62, 9375-9414.	6.4	108
26	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. Journal of Medicinal Chemistry, 2016, 59, 7991-8007.	6.4	107
27	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication. Journal of Medicinal Chemistry, 1991, 34, 2383-2389.	6.4	102
28	Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: Structural modulations of diaryltriazines with potent anti-HIV activity. European Journal of Medicinal Chemistry, 2008, 43, 1230-1236.	5.5	102
29	Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues. Antimicrobial Agents and Chemotherapy, 2000, 44, 2109-2117.	3.2	101
30	New Class of HIV Integrase Inhibitors that Block Viral Replication in Cell Culture. Current Biology, 2002, 12, 1169-1177.	3.9	100
31	Configurationally Restricted Bismacrocyclic CXCR4 Receptor Antagonists. Journal of Medicinal Chemistry, 2006, 49, 6162-6165.	6.4	97
32	Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. European Journal of Medicinal Chemistry, 2008, 43, 2800-2806.	5.5	97
33	SYNTHESIS AND ANTI-HIV ACTIVITY OF NEW MODIFIED 1,2,3-TRIAZOLE ACYCLONUCLEOSIDES. Nucleosides, Nucleotides and Nucleic Acids, 2001, 20, 1949-1960.	1.1	95
34	Pyridine N-oxide derivatives: unusual anti-HIV compounds with multiple mechanisms of antiviral action. Journal of Antimicrobial Chemotherapy, 2005, 55, 135-138.	3.0	95
35	Development of Resistance against Diketo Derivatives of Human Immunodeficiency Virus Type 1 by Progressive Accumulation of Integrase Mutations. Journal of Virology, 2003, 77, 11459-11470.	3.4	94
36	Design Strategies of Novel NNRTIs to Overcome Drug Resistance. Current Medicinal Chemistry, 2009, 16, 3903-3917.	2.4	92

#	Article	IF	Citations
37	Resistance of Human Immunodeficiency Virus Type 1 to the High-Mannose Binding Agents Cyanovirin N and Concanavalin A. Journal of Virology, 2005, 79, 7777-7784.	3.4	89
38	Synthesis and anti-HIV activity of 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole structurally-related 1,2-substituted benzimidazoles. Il Farmaco, 2002, 57, 819-823.	0.9	86
39	2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Antiviral Research, 2004, 63, 79-84.	4.1	86
40	Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chemical Society Reviews, 2021, 50, 4514-4540.	38.1	84
41	Binding Optimization through Coordination Chemistry: CXCR4 Chemokine Receptor Antagonists from Ultrarigid Metal Complexes. Journal of the American Chemical Society, 2009, 131, 3416-3417.	13.7	82
42	Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: Synthesis and preliminary SAR studies. Bioorganic and Medicinal Chemistry, 2009, 17, 5920-5927.	3.0	81
43	A yeast-based model of Î±-synucleinopathy identifies compounds with therapeutic potential. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 312-318.	3.8	79
44	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants. Journal of Medicinal Chemistry, 2017, 60, 4424-4443.	6.4	79
45	Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years. Acta Pharmaceutica Sinica B, 2020, 10, 961-978.	12.0	79
46	Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole rings. Bioorganic and Medicinal Chemistry, 2006, 14, 2366-2374.	3.0	78
47	Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. Aids, 1999, 13, 1477-1483.	2.2	77
48	A Microwave-Assisted Diastereoselective Multicomponent Reaction To Access Dibenzo[c,e]azepinones: Synthesis and Biological Evaluation. Journal of Organic Chemistry, 2011, 76, 2828-2839.	3.2	77
49	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: Optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. European Journal of Medicinal Chemistry, 2015, 92, 754-765.	5.5	76
50	Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-(thi)one derivatives. Il Farmaco, 2002, 57, 747-751.	0.9	75
51	Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells. European Journal of Medicinal Chemistry, 2016, 121, 58-70.	5.5	73
52	Synthesis of (Z) and (E) Î±-alkenyl phosphonic acid derivatives of purines and pyrimidines. Tetrahedron, 1998, 54, 3807-3816.	1.9	72
53	Synthesis and Screening for Anti-HIV Activity of Some N-Mannich Bases of Isatin Derivatives. Chemotherapy, 1999, 45, 192-196.	1.6	71
54	Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. Aids, 2004, 18, 2019-2028.	2.2	71

#	Article	IF	Citations
55	Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: Design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives. Bioorganic and Medicinal Chemistry, 2014, 22, 2052-2059.	3.0	71
56	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1956-1960.	2.2	70
57	Identification of Dihydrofuro[3,4-d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties. Journal of Medicinal Chemistry, 2019, 62, 1484-1501.	6.4	70
58	Synthesis of New Covalently Bound Îº-Carrageenanâˆ'AZT Conjugates with Improved Anti-HIV Activities. Journal of Medicinal Chemistry, 2002, 45, 1275-1283.	6.4	69
59	Synthesis of new 2,3-diaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Il Farmaco, 2004, 59, 33-39.	0.9	69
60	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. European Journal of Medicinal Chemistry, 2018, 151, 339-350.	5.5	68
61	Jatrophane Diterpenes as Inhibitors of Chikungunya Virus Replication: Structureâ€"Activity Relationship and Discovery of a Potent Lead. Journal of Natural Products, 2014, 77, 1505-1512.	3.0	67
62	ANTIVIRAL POTENTIAL OF A NEW GENERATION OF ACYCLIC NUCLEOSIDE PHOSPHONATES, THE 6-[2-(PHOSPHONOMETHOXY)ALKOXY]-2,4-DIAMINOPYRIMIDINES. Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 331-341.	1.1	66
63	Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles. Journal of Medicinal Chemistry, 2019, 62, 2083-2098.	6.4	66
64	Potent Anti-HIV (Type 1 and Type 2) Activity of Polyoxometalates:Â Structureâˆ'Activity Relationship and Mechanism of Action. Journal of Medicinal Chemistry, 2000, 43, 778-783.	6.4	65
65	1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5368-5371.	2.2	65
66	Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3472-3476.	2.2	65
67	Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 5775-5781.	3.0	64
68	1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein. Comptes Rendus De L'AcadÃ©mie Des Sciences SÃ©rie 3, Sciences De La Vie, 2000, 323, 883-894.	0.8	63
69	Antiretrovirus Activity of a Novel Class of Acyclic Pyrimidine Nucleoside Phosphonates. Antimicrobial Agents and Chemotherapy, 2002, 46, 2185-2193.	3.2	63
70	Anti-HIV Activity of Thiosemicarbazone and Semicarbazone Derivatives of (Â±)-3-Menthone. Archiv Der Pharmazie, 2002, 335, 183.	4.1	63
71	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2012, 20, 3856-3864.	3.0	63
72	Synthesis and anti-HIV activity of 1,1,3-trioxo-2 H ,4 H -thieno[3,4- e][1,2,4]thiadiazines (TTDs): a new family of HIV-1 specific non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 1999, 7, 2811-2822.	3.0	62

#	Article	IF	Citations
73	Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones. Il Farmaco, 2003, 58, 115-120.	0.9	62
74	Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication. Journal of Natural Products, 2015, 78, 1277-1283.	3.0	62
75	Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: Structureâ€“activity relationship and mechanism of action. Bioorganic and Medicinal Chemistry, 2008, 16, 9487-9497.	3.0	59
76	Computational Strategies in Discovering Novel Non-nucleoside Inhibitors of HIV-1 RT. Journal of Medicinal Chemistry, 2005, 48, 3433-3437.	6.4	58
77	1,2,3-Selenadiazole thioacetanilides: Synthesis and anti-HIV activity evaluation. Bioorganic and Medicinal Chemistry, 2009, 17, 6374-6379.	3.0	58
78	Screening of Tanzanian Medicinal Plants againstPlasmodium falciparumand Human Immunodeficiency Virus. Planta Medica, 2010, 76, 195-201.	1.3	58
79	Isonicotinic acid hydrazide derivatives: synthesis, antimicrobial activity, and QSAR studies. Medicinal Chemistry Research, 2012, 21, 1451-1470.	2.4	58
80	Ceramide Involvement in Apoptosis and Apoptotic Diseases. Mini-Reviews in Medicinal Chemistry, 2006, 6, 699-709.	2.4	57
81	A new vinyl selenone-based domino approach to spirocyclopropyl oxindoles endowed with anti-HIV RT activity. Organic and Biomolecular Chemistry, 2016, 14, 2015-2024.	2.8	57
82	Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-d]pyrimidine non-nucleoside inhibitors. ELife, 2018, 7, .	6.0	57
83	A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Molecular Pharmacology, 2000, 57, 116-24.	2.3	57
84	Structureâ^'Activity Relationship Study on Anti-HIV 6-Desfluoroquinolones. Journal of Medicinal Chemistry, 2008, 51, 5454-5458.	6.4	56
85	Conversion of 2â€²,3â€²-dideoxyadenosine (ddA) and 2â€²,3â€²-didehydro-2â€²,3â€²-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. FEBS Letters, 1997, 410, 324-328.	2.8	55
86	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazonesâ€“thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 723-727.	2.2	55
87	Synthesis and anti-HIV activity of carboxylated and drug-conjugated multi-walled carbon nanotubes. Carbon, 2015, 82, 548-561.	10.3	55
88	Antiretroviral Activity of Semisynthetic Derivatives of Glycopeptide Antibiotics. Journal of Medicinal Chemistry, 2003, 46, 2755-2764.	6.4	54
89	Synthesis and Studies of New 2â€(Coumarinâ€4â€yloxy)â€4,6â€(substituted)â€sâ€Triazine Derivatives as Potential Antiâ€HIV Agents. Archiv Der Pharmazie, 2009, 342, 281-290.	4.1	54
90	Synthesis, antimycobacterial, antiviral, antimicrobial activities, and QSAR studies of nicotinic acid benzylidene hydrazide derivatives. Medicinal Chemistry Research, 2012, 21, 1557-1576.	2.4	54

#	Article	IF	Citations
91	Synthesis and anti-HIV activity of 4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene) amino]-N(4,6-dimethyl-2-pyrimidinyl)-benzene sulfonamide and its derivatives. European Journal of Pharmaceutical Sciences, 2001, 14, 313-316.	4.0	53
92	Chemical studies of essential oils of Juniperus oxycedrus ssp. badia. Journal of Ethnopharmacology, 2002, 81, 129-134.	4.1	53
93	Zinc(ii) complexes of constrained antiviral macrocycles. Dalton Transactions, 2012, 41, 6408.	3.3	53
94	Inhibition of Human Immunodeficiency Virus Type 1 Integration by Diketo Derivatives. Antimicrobial Agents and Chemotherapy, 2002, 46, 3292-3297.	3.2	52
95	Artemisinin Analogues as Potent Inhibitors of In Vitro Hepatitis C Virus Replication. PLoS ONE, 2013, 8, e81783.	2.5	51
96	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: Discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach. European Journal of Medicinal Chemistry, 2014, 85, 293-303.	5.5	51
97	Design, synthesis, antimicrobial activity and anti-HIV activity evaluation of novel hybrid quinazolineâ€“triazine derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 100-108.	5.2	51
98	Novel Inhibitors of HIV-1 Integration. Current Drug Metabolism, 2004, 5, 291-304.	1.2	51
99	Synthesis and Biological Activity of Novel 1H,3H-Thiazolo[3,4-a]Benzimidazoles: Non-nucleoside Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors. Antiviral Chemistry and Chemotherapy, 1999, 10, 211-217.	0.6	50
100	Heterocyclic rimantadine analogues with antiviral activity. Bioorganic and Medicinal Chemistry, 2003, 11, 5485-5492.	3.0	50
101	Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation. Journal of Antimicrobial Chemotherapy, 2005, 56, 847-855.	3.0	50
102	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7155-7162.	2.2	50
103	The G-quadruplex-forming aptamer AS1411 potently inhibits HIV-1 attachment to the host cell. International Journal of Antimicrobial Agents, 2016, 47, 311-316.	2.5	50
104	Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties. Journal of Medicinal Chemistry, 2020, 63, 4837-4848.	6.4	50
105	Broad-Spectrum Antiviral Activity and Mechanism of Antiviral Action of the Fluoroquinolone Derivative K-12. Antiviral Chemistry and Chemotherapy, 1998, 9, 403-411.	0.6	49
106	Synthesis and Anti-HIV Activity of New Metabolically Stable Alkenyldiarylmethane Non-Nucleoside Reverse Transcriptase Inhibitors Incorporating N-Methoxy Imidoyl Halide and 1,2,4-Oxadiazole Systems. Journal of Medicinal Chemistry, 2007, 50, 3314-3321.	6.4	49
107	Anti-influenza virus activity and structureâ€“activity relationship of aglycoristocetin derivatives with cyclobutenedione carrying hydrophobic chains. Antiviral Research, 2009, 82, 89-94.	4.1	49
108	Design, synthesis of new Î²-carboline derivatives and their selective anti-HIV-2 activity. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1232-1235.	2.2	49

#	Article	IF	Citations
109	Polyanion Inhibitors of HIV and Other Viruses. 7. Polyanionic Compounds and Polyzwitterionic Compounds Derived from Cyclodextrins as Inhibitors of HIV Transmission. Journal of Medicinal Chemistry, 1998, 41, 4927-4932.	6.4	48
110	1,1,3-Trioxo-2 H ,4 H -Thieno[3,4- e][1,2,4]Thiadiazine (TTD) Derivatives: a New Class of Nonnucleoside Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitors with Anti-HIV-1 Activity. Antimicrobial Agents and Chemotherapy, 1998, 42, 618-623.	3.2	48
111	SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus. Antimicrobial Agents and Chemotherapy, 1997, 41, 262-268.	3.2	47
112	Biologically active bisbenzylisoquinoline alkaloids from the root bark of Epinetrum villosum. Journal of Ethnopharmacology, 2005, 102, 89-94.	4.1	47
113	New synthesis and anti-HIV and antiviral properties of 3-arylsulfonyl derivatives of 4-ydroxycoumarin and 4-hydroxyquinolone. Pharmaceutical Chemistry Journal, 2008, 42, 265-270.	0.8	47
114	Synthesis, antiviral and anticancer activity of some novel thioureas derivedfrom N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide. European Journal of Medicinal Chemistry, 2009, 44, 3591-3595.	5.5	47
115	Straightforward synthesis of triazoloacyclonucleotide phosphonates as potential HCV inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7365-7368.	2.2	47
116	Design, synthesis and anti-HIV activity of novel quinoxaline derivatives. European Journal of Medicinal Chemistry, 2016, 117, 230-240.	5.5	47
117	5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3173-3176.	2.2	46
118	Structure Modifications of 6-Aminoquinolones with Potent Anti-HIV Activity1. Journal of Medicinal Chemistry, 2004, 47, 5567-5578.	6.4	45
119	Replacement of the Metabolically Labile Methyl Esters in the Alkenyldiarylmethane Series of Non-Nucleoside Reverse Transcriptase Inhibitors with Isoxazolone, Isoxazole, Oxazolone, or Cyano Substituents. Journal of Medicinal Chemistry, 2006, 49, 5316-5323.	6.4	45
120	Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2009, 44, 4648-4653.	5.5	45
121	Synthesis and Anti-HIV-1 Activity Evaluation of 5-Alkyl-2-alkylthio-6-(arylcarbonyl or) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 267 T Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 1778-1786.	6.4	44
122	Design and synthesis of N1-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 1459-1467.	3.0	44
123	Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Molecular Pharmacology, 2000, 58, 1100-8.	2.3	44
124	Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2008, 16, 7429-7435.	3.0	43
125	Structural Modifications of DAPY Analogues with Potent Antiâ€HIVâ€1 Activity. ChemMedChem, 2009, 4, 219-224.	3.2	43
126	Antimicrobial, anti-TB, anticancer and anti-HIV evaluation of news-triazine-based heterocycles. Future Medicinal Chemistry, 2012, 4, 1053-1065.	2.3	43

#	Article	IF	Citations
127	Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2013, 21, 2128-2134.	3.0	43
128	Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors: Part I. Synthesis and Structure-Activity Relationship of 1-Alkoxymethyl-5-alkyl-6-naphthylmethyl Uracils as HEPT Analogues. Chemical and Pharmaceutical Bulletin, 2003, 51, 779-789.	1.3	42
129	Design, synthesis, and structureâ€"activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents. Bioorganic and Medicinal Chemistry, 2009, 17, 5962-5967.	3.0	42
130	Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2012, 51, 60-66.	5.5	42
131	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1. European Journal of Medicinal Chemistry, 2018, 145, 726-734.	5.5	42
132	Synthesis and biological evaluation of new heterocyclic quinolinones as anti-parasite and anti-HIV drug candidates. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5962-5964.	2.2	41
133	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: Design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. European Journal of Medicinal Chemistry, 2015, 93, 330-337.	5.5	41
134	Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities. Journal of Medicinal Chemistry, 2020, 63, 4790-4810.	6.4	41
135	N-Aminoimidazole Derivatives Inhibiting Retroviral Replication via a Yet Unidentified Mode of Action. Journal of Medicinal Chemistry, 2003, 46, 1546-1553.	6.4	40
136	Synthesis, antimycobacterial, antiviral, antimicrobial activities, and QSAR studies of isonicotinic acid-1-(substituted phenyl)-ethylidene/cycloheptylidene hydrazides. Medicinal Chemistry Research, 2012, 21, 1935-1952.	2.4	40
137	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays. Bioorganic and Medicinal Chemistry, 2014, 22, 1863-1872.	3.0	40
138	Novel 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine Derivatives as Non-Nucleoside Reverse Transcriptase Inhibitors That Inhibit Human Immunodeficiency Virus Type 1 Replication. Journal of Medicinal Chemistry, 1998, 41, 4109-4117.	6.4	39
139	env Chimeric Virus Technology for Evaluating Human Immunodeficiency Virus Susceptibility to Entry Inhibitors. Antimicrobial Agents and Chemotherapy, 2002, 46, 3954-3962.	3.2	39
140	Anti-HIV and antiplasmodial activity of original flavonoid derivatives. Bioorganic and Medicinal Chemistry, 2010, 18, 6012-6023.	3.0	39
141	Oxovanadium(IV) Cyclam and Bicyclam Complexes: Potential CXCR4 Receptor Antagonists. Inorganic Chemistry, 2010, 49, 1122-1132.	4.0	39
142	An Efficient Synthesis of a Hydroxyethylamine (HEA) Isostere and Its Î±â€Aminophosphonate and Phosphoramidate Derivatives as Potential Antiâ€HIV Agents. ChemMedChem, 2012, 7, 1601-1611.	3.2	39
143	Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata. Journal of Natural Products, 2015, 78, 1119-1128.	3.0	39
144	Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus. Organic and Biomolecular Chemistry, 2019, 17, 3202-3217.	2.8	39

#	Article	IF	Citations
145	Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs. Acta Pharmaceutica Sinica B, 2020, 10, 878-894.	12.0	39
146	Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy. Aids, 2001, 15, 33-45.	2.2	38
147	First Synthesis and Evaluation of the Inhibitory Effects of Aza Analogues of TSAO on HIV-1 Replication. Journal of Medicinal Chemistry, 2005, 48, 4276-4284.	6.4	38
148	Design, Synthesis, and SAR of Naphthylâ€Substituted Diarylpyrimidines as Nonâ€Nucleoside Inhibitors of HIVâ€1 Reverse Transcriptase. ChemMedChem, 2009, 4, 1537-1545.	3.2	38
149	Studies into the synthesis of derivatives of 4-amino-2,3-dihydroisothiazole 1,1-dioxides and 4-amino-1,2-oxathiole 2,2-dioxides: The search for linked Ï€-system containing analogues as potential inhibitors of HIV-1 reverse transcriptase. Tetrahedron, 1997, 53, 17795-17814.	1.9	37
150	Halogenated sesquiterpenes from the red alga Laurencia obtusa. Tetrahedron, 2002, 58, 6749-6755.	1.9	37
151	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents. Bioorganic and Medicinal Chemistry, 2011, 19, 5794-5802.	3.0	37
152	Synthesis, Antimycobacterial, Antiviral, Antimicrobial Activity and QSAR Studies of N2-acyl isonicotinic Acid Hydrazide Derivatives. Medicinal Chemistry, 2013, 9, 53-76.	1.5	37
153	Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel. Journal of Medicinal Chemistry, 2020, 63, 1298-1312.	6.4	37
154	Synthesis and biological activity of some 4-substituted 1-[1-(2,3-dihydroxy-1-propoxy)methyl-1,2,3-triazol-(4 & 5)-ylmethyl]-1H-pyrazolo[3,4-d]pyrimidines. Il Farmaco, 2002, 57, 27-32.	0.9	36
155	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 1702-1710.	3.0	36
156	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. European Journal of Medicinal Chemistry, 2014, 87, 52-62.	5.5	36
157	Application of the Triazolization Reaction to Afford Dihydroartemisinin Derivatives with Anti-HIV Activity. Molecules, 2017, 22, 303.	3.8	36
158	New 3â€˜-Azido-3â€˜-deoxythymidin-5â€˜-ylO-(Ï‰-Hydroxyalkyl) Carbonate Prodrugs:Â Synthesis and Anti-HIV Evaluation. Journal of Medicinal Chemistry, 2001, 44, 777-786.	6.4	35
159	Probing key coordination interactions: configurationally restricted metal activated CXCR4 antagonists. Dalton Transactions, 2007, , 5008.	3.3	35
160	CXCR4 chemokine receptor antagonists: nickel(ii) complexes of configurationally restricted macrocycles. Dalton Transactions, 2012, 41, 11369.	3.3	35
161	Inhibition of HIV-1 Replication by a Bis-Thiadiazolbenzene-1,2-Diamine That Chelates Zinc Ions from Retroviral Nucleocapsid Zinc Fingers. Antimicrobial Agents and Chemotherapy, 2010, 54, 1461-1468.	3.2	34
162	Synthesis, crystal structure, anti-HIV, and antiproliferative activity of new oxadiazole and thiazole analogs. Medicinal Chemistry Research, 2016, 25, 2399-2409.	2.4	34

#	Article	IF	Citations
163	Design, Synthesis, Anti-HIV Activities, and Metabolic Stabilities of Alkenyldiarylmethane (ADAM) Non-nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 2004, 47, 3149-3162.	6.4	33
164	Synthesis, Anti-HIV Activity, and Metabolic Stability of New Alkenyldiarylmethane HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 6140-6155.	6.4	33
165	Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 4601-4605.	3.0	33
166	Phytochemical and biological investigations of Elaeodendron schlechteranum. Journal of Ethnopharmacology, 2010, 129, 319-326.	4.1	33
167	2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies. Journal of Medicinal Chemistry, 2021, 64, 4239-4256.	6.4	33
168	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 3729-3757.	6.4	33
169	Studies on anti-HIV quinolones: New insights on the C-6 position. Bioorganic and Medicinal Chemistry, 2009, 17, 667-674.	3.0	32
170	Arylazolylthioacetanilide. Part 8â˜†: Design, synthesis and biological evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides As Potent HIV-1 inhibitors. European Journal of Medicinal Chemistry, 2011, 46, 5039-5045.	5.5	32
171	Computerâ€Aided Design, Synthesis and Validation of 2â€Phenylquinazolinone Fragments as CDK9 Inhibitors with Antiâ€HIVâ€1 Tatâ€Mediated Transcription Activity. ChemMedChem, 2013, 8, 1941-1953.	3.2	32
172	Design, Synthesis, and Molecular Docking Studies of a Conjugated Thiadiazoleâ€“Thiourea Scaffold as Antituberculosis Agents. Biological and Pharmaceutical Bulletin, 2016, 39, 502-515.	1.4	32
173	Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the â€œNNRTI Adjacentâ€• Binding Site. ACS Medicinal Chemistry Letters, 2018, 9, 334-338.	2.8	32
174	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles. Journal of Medicinal Chemistry, 2019, 62, 11430-11436.	6.4	32
175	Synthesis of Novel Derivatives of 4-Amino-3-(2-Furyl)-5-Mercapto-1,2,4-Triazole as Potential HIV-1 NNRTIs. Molecules, 2007, 12, 2003-2016.	3.8	31
176	Synthesis and Biological Evaluation of Alkenyldiarylmethane HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors That Possess Increased Hydrolytic Stability. Journal of Medicinal Chemistry, 2007, 50, 4854-4867.	6.4	31
177	Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2009, 44, 1210-1214.	5.5	31
178	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy. Bioorganic and Medicinal Chemistry, 2010, 18, 5039-5047.	3.0	31
179	Synthesis and Antiâ€HIV Activity of Arylâ€2â€[(4â€cyanophenyl)amino]â€4â€pyrimidinone hydrazones as Potent Nonâ€nucleoside Reverse Transcriptase Inhibitors. ChemMedChem, 2011, 6, 2225-2232.	3.2	31
180	5-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase. European Journal of Medicinal Chemistry, 2018, 155, 714-724.	5.5	31

#	Article	IF	Citations
181	Inhibition of Human Immunodeficiency Virus by a New Class of Pyridine Oxide Derivatives. Antimicrobial Agents and Chemotherapy, 2003, 47, 2951-2957.	3.2	30
182	Structural Investigation of the Naphthyridone Scaffold: Identification of a 1,6â€Naphthyridone Derivative with Potent and Selective Antiâ€HIV Activity. ChemMedChem, 2011, 6, 1249-1257.	3.2	30
183	Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2011, 19, 4366-4376.	3.0	30
184	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization. European Journal of Medicinal Chemistry, 2017, 130, 209-222.	5.5	30
185	Discovery of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP. ACS Medicinal Chemistry Letters, 2017, 8, 1188-1193.	2.8	30
186	Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice. Antimicrobial Agents and Chemotherapy, 1997, 41, 611-616.	3.2	29
187	Pyridine N-oxide derivatives inhibit viral transactivation by interfering with NF-ÎºB binding. Biochemical Pharmacology, 2006, 71, 1122-1135.	4.4	29
188	Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach. European Journal of Medicinal Chemistry, 2014, 80, 112-121.	5.5	29
189	Modification of the length and structure of the linker of N6-benzyladenosine modulates its selective antiviral activity against enterovirus 71. European Journal of Medicinal Chemistry, 2016, 111, 84-94.	5.5	29
190	Synthesis, crystal structure, anti-HIV, and antiproliferative activity of new pyrazolylthiazole derivatives. Medicinal Chemistry Research, 2017, 26, 2653-2665.	2.4	29
191	Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Acta Pharmaceutica Sinica B, 2020, 10, 344-357.	12.0	29
192	Title is missing!. Helvetica Chimica Acta, 2002, 85, 2961-2974.	1.6	28
193	Phosphonates with Antiviral Activity. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 1321-1327.	1.1	28
194	Synthesis of novel PETT analogues: 3,4-dimethoxy phenyl ethyl 1,3,5-triazinyl thiourea derivatives and their antibacterial and anti-HIV studies. Journal of the Brazilian Chemical Society, 2007, 18, .	0.6	28
195	Lead Optimization of Diarylpyrimidines as Nonâ€nucleoside Inhibitors of HIVâ€1 Reverse Transcriptase. ChemMedChem, 2010, 5, 837-840.	3.2	28
196	Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV. Bioorganic and Medicinal Chemistry, 2010, 18, 2370-2374.	3.0	28
197	Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2012, 53, 229-234.	5.5	28
198	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase. Bioorganic and Medicinal Chemistry, 2013, 21, 1150-1158.	3.0	28

#	Article	IF	Citations
199	Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2014, 82, 600-611.	5.5	28
200	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket. European Journal of Medicinal Chemistry, 2016, 109, 294-304.	5.5	28
201	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery. ACS Medicinal Chemistry Letters, 2018, 9, 370-375.	2.8	28
202	Molecular design opportunities presented by solventâ€exposed regions of target proteins. Medicinal Research Reviews, 2019, 39, 2194-2238.	10.5	28
203	S-Adenosylhomocysteine Hydrolase Inhibitors Interfere with the Replication of Human Immunodeficiency Virus Type 1 through Inhibition of the LTR Transactivation. Molecular Pharmacology, 1997, 52, 1157-1163.	2.3	27
204	Synthesis, Structure and in Vitro Anti-Human Immunodeficiency virus Activity of Novel 3-Methyl-1H,3H-Thiazolo[3,4-a]Benzimidazoles. Antiviral Chemistry and Chemotherapy, 1998, 9, 431-438.	0.6	27
205	Evaluating Clinical Isolates for Their Phenotypic and Genotypic Resistance Against Anti-HIV Drugs. , 2000, 24, 223-258.		27
206	Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA. International Journal of Pharmaceutics, 1999, 186, 127-136.	5.2	27
207	New 3â€˜-Azido-3â€˜-deoxythymidin-5â€˜-yl O-(4-Hydroxyalkyl or -Alkenyl or -Alkylepoxide) Carbonate Prodrugs:â€‰Synthesis and Anti-HIV Evaluation. Journal of Medicinal Chemistry, 2001, 44, 3014-3021.	6.4	27
208	Dimer Disruption and Monomer Sequestration by Alkyl Tripeptides Are Successful Strategies for Inhibiting Wild-Type and Multidrug-Resistant Mutated HIV-1 Proteases. Biochemistry, 2009, 48, 379-387.	2.5	27
209	Synthesis, In Vitro and In Vivo Release Kinetics, and Antiâ€HIV Activity of A Sustainedâ€Release Prodrug (mPEGâ€AZT) of 3â€²â€Azidoâ€3â€²â€deoxythymidine (AZT, Zidovudine). ChemMedChem, 2010, 5, 1893-1898.	3.2	27
210	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. European Journal of Medicinal Chemistry, 2016, 121, 352-363.	5.5	27
211	Chelation Motifs Affecting Metal-dependent Viral Enzymes: Nâ€²-acylhydrazone Ligands as Dual Target Inhibitors of HIV-1 Integrase and Reverse Transcriptase Ribonuclease H Domain. Frontiers in Microbiology, 2017, 8, 440.	3.5	27
212	Correlation of Anti-HIV Activity with Anion Spacing in a Series of Cosalane Analogues with Extended Polycarboxylate Pharmacophores. Journal of Medicinal Chemistry, 2001, 44, 703-714.	6.4	26
213	Novel Human Immunodeficiency Virus (HIV) Inhibitors That Have a Dual Mode of Anti-HIV Action. Antimicrobial Agents and Chemotherapy, 2003, 47, 3109-3116.	3.2	26
214	Studies of Antiâ€HIV Transcription Inhibitor Quinolones: Identification of Potent N1â€Vinyl Derivatives. ChemMedChem, 2010, 5, 1880-1892.	3.2	26
215	Substituted 2-aminothiazoles are exceptional inhibitors of neuronal degeneration in tau-driven models of Alzheimerâ€™s disease. European Journal of Pharmaceutical Sciences, 2011, 43, 386-392.	4.0	26
216	Synthesis and structureâ€“activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2011, 19, 5117-5124.	3.0	26

#	Article	IF	Citations
217	Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication. Journal of Medicinal Chemistry, 2016, 59, 9513-9531.	6.4	26
218	Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR. Bioorganic and Medicinal Chemistry, 2017, 25, 2491-2497.	3.0	26
219	Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorganic and Medicinal Chemistry, 2018, 26, 661-674.	3.0	26
220	Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored â€œhydrophobic channelâ€• Organic and Biomolecular Chemistry, 2018, 16, 1014-1028.	2.8	26
221	Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N and E138K Mutants and Pharmacokinetic Profiles. ACS Infectious Diseases, 2020, 6, 787-801.	3.8	26
222	Synthesis and Anti-HIV-1 and Anti-HCMV Activity of 1-Substituted 3-(3,5-Dimethylbenzyl)uracil Derivatives. Chemical and Pharmaceutical Bulletin, 2006, 54, 325-333.	1.3	25
223	POMA analyses as new efficient bioinformaticsâ€™ platform to predict and optimise bioactivity of synthesized 3a,4-dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide/carbothioamide analogues. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7029-7035.	2.2	25
224	Hybrid chemistry. Part 4: Discovery of etravirineâ€“VRX-480773 hybrids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 4248-4255.	3.0	25
225	Anti-HIV diarylpyrimidineâ€“quinolone hybrids and their mode of action. Bioorganic and Medicinal Chemistry, 2015, 23, 3860-3868.	3.0	25
226	Fragment-based discovery of sulfur-containing diarylbenzopyrimidines as novel nonnucleoside reverse transcriptase inhibitors. Chinese Chemical Letters, 2020, 31, 764-768.	9.0	25
227	Synthesis and anti-HIV activity of a bile acid analog of cosalane. Tetrahedron, 2001, 57, 9385-9391.	1.9	24
228	Nitroimidazoles. V. Synthesis and anti-HIV evaluation of new 5-substituted piperazinyl-4-nitroimidazole derivatives. Acta Pharmaceutica, 2007, 57, 379-393.	2.0	24
229	Structureâ€“activity relationships for dipeptide prodrugs of acyclovir: Implications for prodrug design. European Journal of Medicinal Chemistry, 2009, 44, 2339-2346.	5.5	24
230	Synthesis and biological evaluation of novel 2-(substituted) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 Td (phenylaminocarbonylmethylth Bioorganic and Medicinal Chemistry, 2009, 17, 7749-7754.	3.0	24
231	A phenyl-thiadiazolylidene-amine derivative ejects zinc from retroviral nucleocapsid zinc fingers and inactivates HIV virions. Retrovirology, 2012, 9, 95.	2.0	24
232	A stably expressed llama single-domain intrabody targeting Rev displays broad-spectrum anti-HIV activity. Antiviral Research, 2014, 112, 91-102.	4.1	24
233	Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma. EBioMedicine, 2015, 2, 1102-1113.	6.1	24
234	Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors. Communications Chemistry, 2019, 2, .	4.5	24

#	Article	IF	Citations
235	Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2019, 27, 447-456.	3.0	24
236	Synthesis and anti-HIV activity evaluation of novel Nâ€²-arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio]acetohydrazides. Medicinal Chemistry Research, 2010, 19, 652-663.	2.4	23
237	1,2,3â€Thiadiazole Thioacetanilides. Part 2. Chemistry and Biodiversity, 2010, 7, 1717-1727.	2.1	23
238	Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2011, 19, 7093-7099.	3.0	23
239	Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6593-6597.	2.2	23
240	Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2015, 97, 1-9.	5.5	23
241	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue. European Journal of Medicinal Chemistry, 2015, 102, 215-222.	5.5	23
242	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities. Bioorganic and Medicinal Chemistry, 2015, 23, 6587-6593.	3.0	23
243	Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays. Bioorganic and Medicinal Chemistry, 2017, 25, 4397-4406.	3.0	23
244	1,2,4-Triazolo[1,5-a]pyrimidines as a Novel Class of Inhibitors of the HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity. Molecules, 2020, 25, 1183.	3.8	23
245	In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP. European Journal of Medicinal Chemistry, 2020, 193, 112237.	5.5	23
246	Synthesis and anti-HIV Activity of New Fused Chromene Derivatives Derived from 2-Amino-4-(1-naphthyl)-5-oxo-4H,5H-pyrano[3,2- c]chromene-3-carbonitrile. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2013, 68, 229-238.	0.7	22
247	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2019, 182, 111603.	5.5	22
248	Inhibition of Human Immunodeficiency Virus Type (HIV-1) Replication by some Diversely Functionalized Spirocyclopropyl Derivatives. Archiv Der Pharmazie, 1999, 332, 163-166.	4.1	21
249	Synthesis and Antiviral Activity of 1,3-Disubstituted Uracils against HIV-1 and HCMV. Antiviral Chemistry and Chemotherapy, 2003, 14, 271-279.	0.6	21
250	Potent Nonclassical Nucleoside Antiviral Drugs Based on theN,N-Diarylformamidine Concept. Journal of Medicinal Chemistry, 2004, 47, 1183-1192.	6.4	21
251	Nonnucleoside HIV-1 Reverse-Transcriptase Inhibitors, Part 5. Synthesis and Anti-HIV-1 Activity of Novel 6-Naphthylthio HEPT Analogues. Chemical and Pharmaceutical Bulletin, 2005, 53, 886-892.	1.3	21
252	Synthesis and primary antiviral activity evaluation of 3-hydrazono-5-nitro-2-indolinone derivatives. Arkivoc, 2006, 2006, 109-118.	0.5	21

#	Article	IF	Citations
253	Synthesis and anti-HIV evaluation of the novel 2-(m-chlorobenzyl)-4-substituted-7-methyl-1, 1, 3-trioxo-pyrazolo[4, 5-e] [1, 2, 4]thiadiazines. Archives of Pharmacal Research, 2006, 29, 957-962.	6.3	21
254	2â€(2,6â€Dihaloâ€phenyl)â€3â€heteroarylâ€2â€ylmethylâ€1, 3â€thiazolidinâ€4â€ones: Antiâ€HIV agents. Chemical Biology and Drug Design, 2008, 72, 147-154.	3.2	21
255	Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2009, 44, 1016-1023.	5.5	21
256	Simultaneous RNA quantification of human and retroviral genomes reveals intact interferon signaling in HTLV-1-infected CD4+ T cell lines. Virology Journal, 2012, 9, 171.	3.4	21
257	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2014, 22, 633-642.	3.0	21
258	Antiretroviral activity of metal-chelating HIV-1 integrase inhibitors. European Journal of Medicinal Chemistry, 2014, 83, 594-600.	5.5	21
259	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. European Journal of Medicinal Chemistry, 2016, 115, 53-62.	5.5	21
260	Follow on-based optimization of the biphenyl-DAPYs as HIV-1 nonnucleoside reverse transcriptase inhibitors against the wild-type and mutant strains. Bioorganic Chemistry, 2019, 89, 102974.	4.1	21
261	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities. European Journal of Medicinal Chemistry, 2020, 186, 111864.	5.5	21
262	1,2,4-Triazole Derivatives Inhibiting the Human Immunodeficiency Virus Type 1 (HIV-1) in vitro. Helvetica Chimica Acta, 2002, 85, 1883.	1.6	20
263	Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle. Antiviral Research, 2010, 85, 418-421.	4.1	20
264	Anti-HIV, antimycobacterial and antimicrobial studies of newly synthesized 1,2,4-triazole clubbed benzothiazoles. Medicinal Chemistry Research, 2013, 22, 1320-1329.	2.4	20
265	Synthesis and evaluation of antiviral, antitubercular and anticancer activities of some novel thioureas derived from 4-aminobenzohydrazide hydrazones. Marmara Pharmaceutical Journal, 2010, 1, 13-20.	0.5	20
266	Novel In Vivo Model for the Study of Human Immunodeficiency Virus Type 1 Transcription Inhibitors: Evaluation of New 6-Desfluoroquinolone Derivatives. Antimicrobial Agents and Chemotherapy, 2007, 51, 1407-1413.	3.2	19
267	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2013, 65, 134-143.	5.5	19
268	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach. European Journal of Medicinal Chemistry, 2014, 76, 531-538.	5.5	19
269	Synthesis and Antiâ€<scp>HIV</scp> Activity of 4â€(Naphthalenâ€1â€yl)â€1,2,5â€thiadiazolâ€3â€hydroxyl Derivatives. Chemical Biology and Drug Design, 2014, 84, 420-430.	3.2	19
270	Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands. Bioorganic and Medicinal Chemistry, 2014, 22, 4658-4666.	3.0	19

#	Article	IF	Citations
271	SYNTHESIS AND BIOLOGICAL ACTIVITY OF 4-SUBSTITUTED 1-[1-(2-HYDROXYETHOXY)- METHYL-1,2,3-TRIAZOL-(4) Tj ETQq1 1 0.784314 1797-1810.	1.1	18
272	Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones. Bioorganic Chemistry, 2004, 32, 536-548.	4.1	18
273	A Novel and Efficient Approach to Discriminate between Pre- and Post-Transcription HIV Inhibitors. Molecular Pharmacology, 2005, 67, 1574-1580.	2.3	18
274	Dipeptide Derivatives of AZT: Synthesis, Chemical Stability, Activation in Human Plasma, hPEPT1 Affinity, and Antiviral Activity. ChemMedChem, 2008, 3, 970-978.	3.2	18
275	Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2008, 16, 3887-3894.	3.0	18
276	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: Synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation. European Journal of Medicinal Chemistry, 2010, 45, 5985-5997.	5.5	18
277	Cytotoxicity of Natural Compounds Isolated from the Seeds ofGarcinia afzelii. Planta Medica, 2010, 76, 708-712.	1.3	18
278	Synthesis, drug release and anti-HIV activity of a series of PEGylated zidovudine conjugates. International Journal of Biological Macromolecules, 2012, 50, 974-980.	7.5	18
279	Design, Synthesis, and Evaluation of WC5 Analogues as Inhibitors of Human Cytomegalovirus Immediateâ€Earlyâ€...2 Protein, a Promising Target for Antiâ€HCMV Treatment. ChemMedChem, 2013, 8, 1403-1414.	3.2	18
280	Design, Synthesis, and Antiâ€<scp>HIV</scp> Evaluation of Novel Triazine Derivatives Targeting the Entrance Channel of the <scp>NNRTI</scp> Binding Pocket. Chemical Biology and Drug Design, 2015, 86, 122-128.	3.2	18
281	Synthesis of 3-Nitrosoimidazo[1,2-a]pyridine Derivatives as Potential Antiretroviral Agents. Archiv Der Pharmazie, 2001, 334, 224-228.	4.1	17
282	Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors, Part 7. Synthesis, Antiviral Activity, and 3D-QSAR Investigations of Novel 6-(1-Naphthoyl) HEPT Analogues. Chemical and Pharmaceutical Bulletin, 2006, 54, 1248-1253.	1.3	17
283	Synthesis and antiâ€HIV activity of new 2â€thiolumazine and 2â€thiouracil metal complexes. Heteroatom Chemistry, 2011, 22, 44-50.	0.7	17
284	Arylazolyl(azinyl)thioacetanilides. Part 10: Design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors. Bioorganic and Medicinal Chemistry, 2012, 20, 5527-5536.	3.0	17
285	Synthesis and Biological Evaluation of a Series of 2â€((1â€substitutedâ€1Hâ€1,2,3â€triazolâ€4â€yl)methylthio)â€6â€(naphthalenâ€1â€ylmethyl)pyrimidinâ€4(3H)â€one Potential <scp>HIV</scp>â€1 Inhibitors. Chemical Biology and Drug Design, 2015, 86, 614-618.	3.2	17
286	Synthesis and Preliminary Antiviral Activities of Piperidineâ€substituted Purines against <scp>HIV</scp> and Influenza A/H1N1 Infections. Chemical Biology and Drug Design, 2015, 86, 568-577.	3.2	17
287	Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement. European Journal of Medicinal Chemistry, 2017, 126, 190-201.	5.5	17
288	Silibinin phosphodiester glyco-conjugates: Synthesis, redox behaviour and biological investigations. Bioorganic Chemistry, 2018, 77, 349-359.	4.1	17

#	Article	IF	Citations
289	Dimeric building blocks with N-cyanoguanidine linkage for oligonucleotide synthesis. Tetrahedron Letters, 1992, 33, 7609-7612.	1.4	16
290	SYNTHESIS AND BIOLOGICAL EVALUATION OF SOME 4-SUBSTITUTED 1-[1-(4-HYDROXYBUTYL)-1,2,3-TRIAZOL-(4) Tj ETQq0 0 0 rgBT /Ov 1811-1821.	1.1	16
291	Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype. Aids, 2001, 15, 553-561.	2.2	16
292	Potent and Selective Inhibition of HIV and SIV by Prostratin Interacting with Viral Entry. Antiviral Chemistry and Chemotherapy, 2003, 14, 321-328.	0.6	16
293	Synthesis and anti-HIV activity evaluation of 1-[(alkenyl or alkynyl or) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 587 Td (alkyloxy)me transcriptase inhibitors. European Journal of Medicinal Chemistry, 2007, 42, 198-204.	5.5	16
294	Nicotinic Acid Benzylidene/Phenyl-Ethylidene Hydrazides: Synthesis, Antimicrobial Evaluation and QSAR Studies. Letters in Drug Design and Discovery, 2011, 8, 733-749.	0.7	16
295	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 3220-3226.	3.0	16
296	Different Heterocycles Functionalized sâ€Triazine Analogues: Design, Synthesis and In Vitro Antimicrobial, Antituberculosis, and Antiâ€HIV Assessment. Journal of Heterocyclic Chemistry, 2014, 51, 1641-1658.	2.6	16
297	Synthesis and biological evaluation of some new 1,3,4-thiadiazole and 1,2,4-triazole derivatives from L-methionine as antituberculosis and antiviral agents. Marmara Pharmaceutical Journal, 2015, 2, 88-88.	0.5	16
298	1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries. Bioorganic and Medicinal Chemistry, 2017, 25, 5779-5789.	3.0	16
299	Anti-HIV activity of new higher order G-quadruplex aptamers obtained from tetra-end-linked oligonucleotides. Organic and Biomolecular Chemistry, 2018, 16, 2349-2355.	2.8	16
300	Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3491-3495.	2.2	16
301	Design, synthesis, and antiviral evaluation of novel hydrazone-substituted thiophene[3,2-d]pyrimidine derivatives as potent human immunodeficiency virus-1 inhibitors. Chemical Biology and Drug Design, 2018, 92, 2009-2021.	3.2	16
302	Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing. European Journal of Medicinal Chemistry, 2019, 182, 111619.	5.5	16
303	From cycloheptathiophene-3-carboxamide to oxazinone-based derivatives as allosteric HIV-1 ribonuclease H inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 55-74.	5.2	16
304	Design, synthesis, and biological evaluation of piperidinylâ€substituted [1,2,4]triazolo[1,5â€a]pyrimidine derivatives as potential antiâ€HIVâ€1 agents with reduced cytotoxicity. Chemical Biology and Drug Design, 2021, 97, 67-76.	3.2	16
305	Boronic acid-containing diarylpyrimidine derivatives as novel HIV-1 NNRTIs: Design, synthesis and biological evaluation. Chinese Chemical Letters, 2021, 32, 4053-4057.	9.0	16
306	Synthesis and anti-HIV activity of some new aminoadamantane heterocycles. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1887-1890.	2.2	15

#	Article	IF	Citations
307	Synthesis of aryl semicarbazone of 4-aminoacetophenone and their anti-HIV activity. Pharmaceutica Acta Helvetiae, 1998, 73, 215-218.	1.2	15
308	Extension of the Polyanionic Cosalane Pharmacophore as a Strategy for Increasing Anti-HIV Potency. Journal of Medicinal Chemistry, 1999, 42, 1767-1777.	6.4	15
309	Synthesis and anti-HIV activity of cosalane analogues incorporating nitrogen in the linker chain. Bioorganic and Medicinal Chemistry, 2000, 8, 191-200.	3.0	15
310	Nitroimidazoles, Part 2. Chemistry and Biodiversity, 2006, 3, 515-526.	2.1	15
311	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach. Bioorganic and Medicinal Chemistry, 2012, 20, 6795-6802.	3.0	15
312	Discovery of Piperidine-Linked Pyridine Analogues as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. ChemMedChem, 2013, 8, 1117-1126.	3.2	15
313	Synthesis, and prediction of molecular properties and antimicrobial activity of some acylhydrazones derived from N-(arylsulfonyl)methionine. Turkish Journal of Chemistry, 2016, 40, 510-534.	1.2	15
314	Studies on Cycloheptathiopheneâ€3â€carboxamide Derivatives as Allosteric HIVâ€1 Ribonucleaseâ€…H Inhibitors. ChemMedChem, 2016, 11, 1709-1720.	3.2	15
315	Design, synthesis, and evaluation of â€œdual-siteâ€•binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase. European Journal of Medicinal Chemistry, 2021, 211, 113063.	5.5	15
316	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp3 values and favorable drug-like properties. European Journal of Medicinal Chemistry, 2021, 213, 113051.	5.5	15
317	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs. Journal of Medicinal Chemistry, 2021, 64, 10297-10311.	6.4	15
318	Design, synthesis, and mechanism study of dimerized phenylalanine derivatives as novel HIV-1 capsid inhibitors. European Journal of Medicinal Chemistry, 2021, 226, 113848.	5.5	15
319	Synthesis and Anti-HIV Activity of Cosalane Analogues with Substituted Benzoic Acid Rings Attached to the Pharmacophore through Methylene and Amide Linkers. Journal of Organic Chemistry, 1999, 64, 5858-5866.	3.2	14
320	Synthesis and anti-HIV1 biological activity of novel 5â€³-ATSAO compounds. Bioorganic and Medicinal Chemistry, 2008, 16, 4733-4741.	3.0	14
321	Sydnone Sulfonamide Derivatives as Antibacterial, Antifungal, Antiproliferative and Anti-HIV Agents. Pharmaceutical Chemistry Journal, 2014, 48, 260-268.	0.8	14
322	Scaffold hopping: Exploration of acetanilide-containing uracil analogues as potential NNRTIs. Bioorganic and Medicinal Chemistry, 2015, 23, 1069-1081.	3.0	14
323	Searching for novel N 1 -substituted benzimidazol-2-ones as non-nucleoside HIV-1 RT inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 3861-3870.	3.0	14
324	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1640-1643.	2.2	14

#	Article	IF	Citations
325	Design, synthesis, and biologic evaluation of novel galloyl derivatives as <scp>HIV</scp>â€1 <scp>RN</scp>ase H inhibitors. Chemical Biology and Drug Design, 2019, 93, 582-589.	3.2	14
326	Privileged scaffold inspired design of novel oxime-biphenyl-DAPYs in treatment of HIV-1. Bioorganic Chemistry, 2020, 99, 103825.	4.1	14
327	Discovery of Novel Dihydrothiopyrano[4,3-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles. Journal of Medicinal Chemistry, 2021, 64, 13658-13675.	6.4	14
328	Synthesis and Anti-HIV Evaluation of Novel 1,2,4-triazole Derivatives as Potential Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. Letters in Drug Design and Discovery, 2013, 10, 27-34.	0.7	14
329	Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. Part 13. Chemistry and Biodiversity, 2009, 6, 561-568.	2.1	13
330	Design, synthesis and preliminary antiviral screening of new N-phenylpyrazole and dihydroisoxazole derivatives. Medicinal Chemistry Research, 2010, 19, 1025-1035.	2.4	13
331	Synthesis and Biological Evaluation of 6â€Substituted 5â€Alkylâ€2â€(phenylaminocarbonylmethylthio)pyrimidinâ€4(3H)â€ones as Potent HIVâ€1 NNRTIs. ChemMedChem, 2011, 6, 826-833.	3.2	13
332	Synthesis and Evaluation of Novel 4â€Substituted Styryl Quinazolines as Potential Antimicrobial Agents. Archiv Der Pharmazie, 2012, 345, 964-972.	4.1	13
333	Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents. Archives of Pharmacal Research, 2012, 35, 975-986.	6.3	13
334	Synthesis and Biological Evaluation of Methylenecyclopropane Analogues of Nucleosides. Synthesis, 2013, 45, 2612-2618.	2.3	13
335	Discovery of HIVâ€1 Integrase Inhibitors: Pharmacophore Mapping, Virtual Screening, Molecular Docking, Synthesis, and Biological Evaluation. Chemical Biology and Drug Design, 2014, 83, 154-166.	3.2	13
336	Synthesis and biological evaluation of DAPYâ€“DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorganic and Medicinal Chemistry, 2015, 23, 624-631.	3.0	13
337	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1348-1351.	2.2	13
338	Discovery of potent <scp>HIV</scp>â€1 nonâ€nucleoside reverse transcriptase inhibitors by exploring the structureâ€“activity relationship of solventâ€exposed regions I. Chemical Biology and Drug Design, 2019, 93, 430-437.	3.2	13
339	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2020, 202, 112549.	5.5	13
340	A Novel Series of Indole Alkaloid Derivatives Inhibit Dengue and Zika Virus Infection by Interference with the Viral Replication Complex. Antimicrobial Agents and Chemotherapy, 2021, 65, e0234920.	3.2	13
341	3-Benzamido, Ureido and Thioureidoimidazo[1,2-a]pyridine Derivatives as Potential Antiviral Agents.. Chemical and Pharmaceutical Bulletin, 2001, 49, 1631-1635.	1.3	12
342	Are 5â€²-O-Carbamate-2â€²,3â€²-dideoxythiacytidine New Anti-HIV and Anti-HBV nucleoside Drugs or Prodrugs?. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2459-2463.	2.2	12

#	Article	IF	Citations
343	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 2535-2541.	3.0	12
344	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach. Bioorganic and Medicinal Chemistry, 2016, 24, 4424-4433.	3.0	12
345	Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5â€b]pyridinâ€2â€ylthioacetanilides as Potent HIV NNRTIs Via a Structureâ€based Bioisosterism Approach. Chemical Biology and Drug Design, 2016, 88, 241-253.	3.2	12
346	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs. European Journal of Medicinal Chemistry, 2017, 140, 383-391.	5.5	12
347	Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase. Bioorganic and Medicinal Chemistry, 2019, 27, 3836-3845.	3.0	12
348	Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126721.	2.2	12
349	Structureâ€“Activity Relationship Exploration of NNIBP Tolerant Region I Leads to Potent HIV-1 NNRTIs. ACS Infectious Diseases, 2020, 6, 2225-2234.	3.8	12
350	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from N-Alkylation to Methyl Hopping on the Pyrimidine Ring. Journal of Medicinal Chemistry, 2021, 64, 5067-5081.	6.4	12
351	The Cellular Thioredoxin-1/Thioredoxin Reductase-1 Driven Oxidoreduction Represents a Chemotherapeutic Target for HIV-1 Entry Inhibition. PLoS ONE, 2016, 11, e0147773.	2.5	12
352	In vitro evaluation of the effect of temporary removal of HIV drug pressure. Antiviral Research, 2000, 46, 215-221.	4.1	11
353	9-(2-Aryloxyethyl) Derivatives of Adenine - a New Class of Non-nucleosidic Antiviral Agents. Chemistry of Heterocyclic Compounds, 2003, 39, 1218-1226.	1.2	11
354	Isothiazole Derivatives as Novel HIV Replication Inhibitors. Antiviral Chemistry and Chemotherapy, 2004, 15, 201-205.	0.6	11
355	Nonâ€Nucleoside HIVâ€1 Reverseâ€Transcriptase Inhibitors. Part 10. Chemistry and Biodiversity, 2008, 5, 168-176.	2.1	11
356	The Phthalocyanine Prototype Derivative Alcian Blue Is the First Synthetic Agent with Selective Anti-Human Immunodeficiency Virus Activity Due to Its gp120 Glycan-Binding Potential. Antimicrobial Agents and Chemotherapy, 2009, 53, 4852-4859.	3.2	11
357	Crystallographic Study of a Novel Subnanomolar Inhibitor Provides Insight on the Binding Interactions of Alkenyldiarylmethanes with Human Immunodeficiency Virus-1 Reverse Transcriptase. Journal of Medicinal Chemistry, 2009, 52, 6467-6473.	6.4	11
358	Synthesis of novel biologically active methylene derivatives of sydnones. Medicinal Chemistry Research, 2013, 22, 5752-5763.	2.4	11
359	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 5290-5297.	3.0	11
360	Structural modification of diarylpyrimidine derivatives as HIV-1 reverse transcriptase inhibitors. Medicinal Chemistry Research, 2015, 24, 220-225.	2.4	11

#	Article	IF	Citations
361	New findings on the d(TGGGAG) sequence: Surprising anti-HIV-1 activity. European Journal of Medicinal Chemistry, 2018, 145, 425-430.	5.5	11
362	Synthesis and biological evaluation of dihydroquinazoline-2-amines as potent non-nucleoside reverse transcriptase inhibitors of wild-type and mutant HIV-1 strains. European Journal of Medicinal Chemistry, 2019, 176, 11-20.	5.5	11
363	Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy. Molecules, 2020, 25, 1050.	3.8	11
364	Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C. Bioorganic and Medicinal Chemistry, 2021, 30, 115927.	3.0	11
365	Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorganic Chemistry, 2020, 96, 103595.	4.1	11
366	Design, synthesis, and mechanistic investigations of phenylalanine derivatives containing a benzothiazole moiety as HIV-1 capsid inhibitors with improved metabolic stability. European Journal of Medicinal Chemistry, 2022, 227, 113903.	5.5	11
367	Synthesis, enzymatic stability and physicochemical properties of oligonucleotides containing a N-cyanoguanidine linkage.. Tetrahedron, 1994, 50, 7231-7246.	1.9	10
368	Synthesis and Antiviral Activities of Some New 5-Heteroaromatic Substituted Derivatives of 2'-Deoxyuridine. Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 525-528.	1.1	10
369	Nitroimidazoles Part 6. Synthesis, Structure andin Vitroanti-HIV Activity of New 5-substituted Piperazinyl-4-nitroimidazole Derivatives. Antiviral Chemistry and Chemotherapy, 2007, 18, 191-200.	0.6	10
370	Synthesis and anti-HIV evaluation of novel 1,3-disubstituted thieno[3,2-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxides(TTDDs). Bioorganic and Medicinal Chemistry, 2008, 16, 157-163.	3.0	10
371	Measuring cooperative Rev protein-protein interactions on Rev responsive RNA by fluorescence resonance energy transfer. RNA Biology, 2011, 8, 316-324.	3.1	10
372	Nitroimidazoles Part 7. Synthesis and Anti-HIV Activity of New 4-Nitroimidazole Derivatives. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2012, 67, 835-842.	0.7	10
373	Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2013, 21, 7091-7100.	3.0	10
374	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2. Bioorganic and Medicinal Chemistry, 2018, 26, 2051-2060.	3.0	10
375	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. European Journal of Medicinal Chemistry, 2020, 206, 112811.	5.5	10
376	Inhibition of HIV-1 RT activity by a new series of 3-(1,3,4-thiadiazol-2-yl)thiazolidin-4-one derivatives. Bioorganic and Medicinal Chemistry, 2020, 28, 115431.	3.0	10
377	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2021, 64, 13604-13621.	6.4	10
378	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. European Journal of Medicinal Chemistry, 2021, 226, 113868.	5.5	10

#	Article	IF	Citations
379	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK. Journal of Medicinal Chemistry, 2022, 65, 2122-2138.	6.4	10
380	Development of Novel Dihydrofuro[3,4-d]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C. Journal of Medicinal Chemistry, 2022, 65, 2458-2470.	6.4	10
381	Synthesis, Biological Activity, Pharmacokinetic Properties and Molecular Modelling Studies of Novel 1H,3H-Oxazolo[3,4-a]Benzimidazoles: Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. Antiviral Chemistry and Chemotherapy, 2001, 12, 169-174.	0.6	9
382	Synthesis and in vitro evaluation of S-acyl-3-thiopropyl prodrugs of Foscarnet. Bioorganic and Medicinal Chemistry, 2004, 12, 1393-1402.	3.0	9
383	Chemoenzymatic Syntheses of Homoâ€•and Heterodimers of AZT and d4T, and Evaluation of Their Antiâ€HIV Activity. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 701-714.	1.1	9
384	Non-nucleoside HIV Reverse Transcriptase Inhibitors, Part 6[1]: Synthesis and Anti-HIV Activity of Novel 2-[(Arylcarbonylmethyl)thio]-6-arylthio DABO Analogues. Archiv Der Pharmazie, 2005, 338, 457-461.	4.1	9
385	Synthesis and Anti-HIV Activity of Novel Cyclopentenyl Nucleoside Analogues of 8-Azapurine. Chemical and Pharmaceutical Bulletin, 2006, 54, 1418-1420.	1.3	9
386	Antiviral Activity of 3-(3,5-Dimethylbenzyl)Uracil Derivatives Against Hiv-1 and HCMV. Nucleosides, Nucleotides and Nucleic Acids, 2007, 26, 1553-1558.	1.1	9
387	Synthesis, anti-HIV-1 activity, and modeling studies of N-3 Boc TSAO compound. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2277-2281.	2.2	9
388	Nitroimidazoles Part 8. Synthesis and Anti-HIV Activity of New 4-Nitroimidazole Derivatives Using the Suzuki Cross-Coupling Reaction. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2012, 67, 925-934.	0.7	9
389	Synthesis and anti-HIV evaluation of new 2-Thioxoimidazolidin-4-ones and their Arylidine (styryl) derivatives. Pharmaceutical Chemistry Journal, 2012, 46, 165-170.	0.8	9
390	Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2020, 185, 111874.	5.5	9
391	Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors. European Journal of Medicinal Chemistry, 2021, 225, 113769.	5.5	9
392	Arylazolylthioacetanilide. Part 11: Design, Synthesis and Biological Evaluation of 1,2,4-triazole Thioacetanilide Derivatives as Novel Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. Medicinal Chemistry, 2013, 9, 968-973.	1.5	9
393	New Substituted Thiazol-2-ylidene-benzamides and Their Reaction with 1-Aza-2-azoniaallene Salts. Synthesis and anti-HIV Activity. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2011, 66, 0512.	0.7	9
394	2â€²-Deoxyuridines with a 5-Heteroaromatic Substituent: Synthesis and Biological Evaluation. Antiviral Chemistry and Chemotherapy, 1995, 6, 262-270.	0.6	8
395	Synthesis and anti-HIV activity of cosalane analogues incorporating two dichlorodisalicylmethane pharmacophore fragments. Bioorganic and Medicinal Chemistry, 2001, 9, 2827-2841.	3.0	8
396	Discovery of a Tat HIV-1 Inhibitor through Computer-Aided Drug Design. Spectroscopy, 2003, 17, 639-645.	0.8	8

#	Article	IF	Citations
397	Inhibition of human immunodeficiency virus type 1 transcription by N-aminoimidazole derivatives. Virology, 2007, 365, 220-237.	2.4	8
398	Synthesis and Antiâ€HIV Activity Evaluation of Novel 2,4â€Disubstituted 7â€Methylâ€1,1,3â€trioxoâ€2,4â€dihydroâ€pyrazoloâ€[4,5â€e][1,2]thiadiazines. Archiv Der Pharmazie, 2008, 341, 216-222.	1.8	8
399	Synthesis and anti-HIV Activity of New Benzimidazole, Benzothiazole and Carbohyrazide Derivatives of the anti-Inflammatory Drug Indomethacin. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2011, 66, 953-960.	0.7	8
400	Synthesis, and in vitro Enzymatic and Antiviral Evaluation of d4T Polyphosphate Derivatives as Chain Terminators. Chemistry and Biodiversity, 2012, 9, 2186-2194.	2.1	8
401	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: Synthesis, biological investigation and molecular modeling studies. Bioorganic and Medicinal Chemistry, 2013, 21, 6477-6483.	3.0	8
402	Discovery of novel pyridazinylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach. MedChemComm, 2013, 4, 810.	3.4	8
403	Exploration of the in vitro Antiviral Activity of a Series of New Pyrimidine Analogues on the Replication of HIV and HCV. Antiviral Chemistry and Chemotherapy, 2013, 23, 103-112.	0.6	8
404	Design and synthesis of a new series of cyclopropylamino-linking diarylpyrimidines as HIV non-nucleoside reverse transcriptase inhibitors. European Journal of Pharmaceutical Sciences, 2014, 62, 334-341.	4.0	8
405	Design, Synthesis, and Biological Evaluation of Novel 2-(Pyridin-3-yloxy)acetamide Derivatives as Potential Anti-HIV-1 Agents. Chemical Biology and Drug Design, 2016, 87, 283-289.	3.2	8
406	1,6-Bis[(benzyloxy)methyl]uracil derivativesâ€”Novel antivirals with activity against HIV-1 and influenza H1N1 virus. Bioorganic and Medicinal Chemistry, 2016, 24, 2476-2485.	3.0	8
407	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy. Bioorganic and Medicinal Chemistry, 2016, 24, 3006-3022.	3.0	8
408	New chalcones and thiopyrimidine analogues derived from mefenamic acid: microwave-assisted synthesis, anti-HIV activity and cytotoxicity as antileukemic agents. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2017, 72, 249-256.	0.7	8
409	Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs. Molecules, 2020, 25, 1581.	3.8	8
410	Tryptophan Trimers and Tetramers Inhibit Dengue and Zika Virus Replication by Interfering with Viral Attachment Processes. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	8
411	Deciphering the Role of Extracellular Vesicles Derived from ZIKV-Infected hcMEC/D3 Cells on the Bloodâ€“Brain Barrier System. Viruses, 2021, 13, 2363.	3.3	8
412	Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIVâ€‘1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2022, 53, 116531.	3.0	8
413	Anti-HIV activity of a series of cosalane amino acid conjugates. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2505-2508.	2.2	7
414	How a Modification (8â€Azaâ€3â€deazaâ€2â€²â€deoxyguanosine) Influences the Quadruplex Structure of Hotoda's 6â€Mer TGGGAG with 5â€²â€and 3â€²â€End Modifications. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 77-88.	1.1	7

#	Article	IF	Citations
415	Isothiazole Derivatives as Antiviral Agents. Antiviral Chemistry and Chemotherapy, 2007, 18, 277-283.	0.6	7
416	Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways. Infection, Genetics and Evolution, 2007, 7, 600-603.	2.3	7
417	Inhibition of tubulin polymerization by select alkenyldiarylmethanes. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 469-473.	2.2	7
418	Synthesis, structureâ€“activity relationship and antiviral activity of 3â€²-N,N-dimethylamino-2â€²,3â€²-dideoxythymidine and its prodrugsâ˜†. European Journal of Medicinal Chemistry, 2010, 45, 3787-3793.	3.5	7
419	Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2013, 21, 7398-7405.	3.0	7
420	Amino acid derivatives. Part 6. Synthesis, in vitro antiviral activity and molecular docking study of new N-Î±-amino acid derivatives conjugated spacer phthalimide backbone. Medicinal Chemistry Research, 2016, 25, 2578-2588.	2.4	7
421	Structure-based linker optimization of 6-(2-cyclohexyl-1-alkyl)-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Chinese Chemical Letters, 2021, 32, 1020-1024.	9.0	7
422	Synthesis, antiviral and cytotoxicity studies of novel N-substituted indophenazine derivatives. Indian Journal of Pharmaceutical Sciences, 2012, 74, 275.	1.0	7
423	SYNTHESIS OFN⁶-ALKYLATED ADENOSINE DERIVATIVES. Nucleosides & Nucleotides, 1996, 15, 1863-1869.	0.5	6
424	Anti-HIV-1 Activity of Benzothiadiazine Dioxide. Antiviral Chemistry and Chemotherapy, 2001, 12, 347-351.	0.6	6
425	Identification of Novel Non-nucleoside Reverse Transcriptase Inhibitors Using Fragment-based Lead Generation. Medicinal Chemistry Research, 2005, 14, 475-487.	2.4	6
426	Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors, Part 4[1]. Synthesis and Anti-HIV Activity of N-1-Î²-Carbonyl-6-naphthyl-methyl Analogues of HEPT. Monatshefte FÃ¼r Chemie, 2005, 136, 1233-1245.	1.8	6
427	Design, Synthesis, and Biological Evaluation of Novel 3,5â€Disubstitutedâ€1,2,6â€Thiadiazineâ€1,1â€Dione Derivatives as <scp>HIV</scp>â€1 <scp>NNRTI</scp>s. Chemical Biology and Drug Design, 2013, 82, 384-393.	3.2	6
428	Synthesis and biological evaluation of new conformationally restricted S-DABO hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase. MedChemComm, 2014, 5, 468.	3.4	6
429	Design, Synthesis, and Biological Evaluation of Novel 4â€Aminopiperidinylâ€linked 3,5â€Disubstitutedâ€1,2,6â€thiadiazineâ€1,1â€dione Derivatives as <scp>HIV</scp>â€1 <scp>NNRTI</scp>s. Chemical Biology and Drug Design, 2015, 86, 107-113.	3.2	6
430	Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket. European Journal of Medicinal Chemistry, 2021, 214, 113204.	5.5	6
431	Design, Synthesis and Biological Evaluation of Substituted Guanidine Indole Derivatives as Potential Inhibitors of HIV-1 Tat-TAR Interaction. Medicinal Chemistry, 2013, 10, 738-746.	1.5	6
432	Amino acid derivatives. Part 5. Synthesis and anti-HIV activity of new sebacoyl precursor derived thioureido-amino acid and phthalimide derivatives. Arkivoc, 2010, 2010, 185-195.	0.5	6

#	Article	IF	Citations
433	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features. European Journal of Medicinal Chemistry, 2022, 238, 114471.	5.5	6
434	From design to biological mechanism evaluation of phenylalanine-bearing HIV-1 capsid inhibitors targeting a vital assembly interface. Chinese Chemical Letters, 2023, 34, 107611.	9.0	6
435	Identification of optimal anion spacing for anti-HIV activity in a series of cosalane tetracarboxylates. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2149-2152.	2.2	5
436	Synthesis and Antiviral Activities of 3-Aralkyl-Thiomethylimidazo[1,2-b]Pyridazine Derivatives. Antiviral Chemistry and Chemotherapy, 2003, 14, 177-182.	0.6	5
437	Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1530-1533.	2.2	5
438	Microwave-Assisted Synthesis and Anti-HIV Activity of New AcyclicC-Nucleosides of 3-(D-Ribo-Tetritol-1-yl)-5-Mercapto-1,2,4-Triazoles. Part 1. Nucleosides, Nucleotides and Nucleic Acids, 2008, 27, 469-483.	1.1	5
439	Sodium and potassium benzeneazophosphonate complexes with crown ethers: Solid-state microwave synthesis, characterization and biological activity. Polyhedron, 2009, 28, 3449-3458.	2.2	5
440	Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2012, 58, 485-492.	5.5	5
441	Synthesis and in vitro enzymatic and antiviral evaluation of phosphoramidate d4T derivatives as chain terminators. Organic and Biomolecular Chemistry, 2012, 10, 146-153.	2.8	5
442	Some Hydrazones of 2â€Aroylaminoâ€3â€methylbutanohydrazide: Synthesis, Molecular Modeling Studies, and Identification as Stereoselective Inhibitors of HIVâ€1. Archiv Der Pharmazie, 2013, 346, 140-153.	4.1	5
443	Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 817-820.	2.2	5
444	Synthesis and in Vitro Antiviral Activities of [(Dihydrofuranâ€2â€yl)oxy]methylâ€phosphonate Nucleosides with 2â€Substituted Adenine as Base. Chemistry and Biodiversity, 2015, 12, 813-822.	2.1	5
445	Regioselective Suzukiâ€“Miyaura reactions of 4,7-dichloro-N-methylisatin. Synthesis, anti-HIV activity and modeling study. RSC Advances, 2015, 5, 107360-107369.	3.6	5
446	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2021, 40, 116195.	3.0	5
447	Design, synthesis, and antiviral evaluation of novel piperidine-substituted arylpyrimidines as HIV-1 NNRTIs by exploring the hydrophobic channel of NNIBP. Bioorganic Chemistry, 2021, 116, 105353.	4.1	5
448	Structural Modifications of Diarylpyrimidine-quinolone Hybrids as Potent HIV-1 NNRTIs with an Improved Drug Resistance Profile. Current Pharmaceutical Design, 2017, 22, 6982-6987.	1.9	5
449	Synthesis, antiviral and cytotoxic activities of 2-(2-Phenyl carboxylic acid)-3-Phenylquinazolin -4(3H)-one derivatives. Indian Journal of Pharmaceutical Sciences, 2010, 72, 806.	1.0	5
450	Discovery of novel biphenyl-substituted pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with promising oral bioavailability. European Journal of Medicinal Chemistry, 2022, 240, 114581.	5.5	5

#	Article	IF	Citations
451	Synthesis and antiviral evaluation of 3â€²-substituted thymidine analogues derived from 3â€²-amino-3â€²-deoxythymidine. Tetrahedron, 1995, 51, 5369-5380.	1.9	4
452	Pyridazines 92. Synthesis of dialkyldipyridazinodiazepinones as potential HIVâ€1 reverse transcriptase inhibitors. Journal of Heterocyclic Chemistry, 2001, 38, 125-130.	2.6	4
453	Synthesis of New Homo and Heterodimers of 2â€²,3â€²-Dideoxyinosine (ddi) Using Ester Linkages. Nucleosides, Nucleotides and Nucleic Acids, 2003, 22, 829-831.	1.1	4
454	New AZT Analogues Having 5â€²-Alkylsulfonyl Groups: Synthesis and Anti-HIV Activity. Nucleosides, Nucleotides and Nucleic Acids, 2007, 26, 223-230.	1.1	4
455	Synthesis and antiviral evaluation of base-modified deoxythreosyl nucleoside phosphonates. Organic and Biomolecular Chemistry, 2017, 15, 5513-5528.	2.8	4
456	Synthesis, In Vitro Anti-HIV Activity, Cytotoxicity, and Computational Studies of Some New Steroids and Their Pyrazoline and Oxime Analogues. Russian Journal of Bioorganic Chemistry, 2020, 46, 822-836.	1.0	4
457	G-Quadruplexes in the Human Immunodeficiency Virus-1 and Herpes Simplex Virus-1: New Targets for Antiviral Activity by Small Molecules. IFMBE Proceedings, 2015, , 207-210.	0.3	4
458	Structure-Based Discovery of Novel NH₂-Biphenyl-Diarylpyrimidines as Potent Non-Nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Safety: From NH₂-Naphthyl-Diarylpyrimidine to NH₂-Biphenyl-Diarylpyrimidine. Journal of Medicinal Chemistry, 2022, 65, 8478-8492.	6.4	4
459	Design, synthesis, and biological evaluation of novel double-winged galloyl derivatives as HIV-1 RNase H inhibitors. European Journal of Medicinal Chemistry, 2022, 240, 114563.	5.5	4
460	Synthesis, Antiretroviral and Antioxidant Evaluation of a Series of New Benzo[b]furan Derivatives. Arzneimittelforschung, 2001, 51, 156-162.	0.4	3
461	HIV-1 Rev function as target for antiretroviral drug development. Current Opinion in HIV and AIDS, 2006, 1, 388-397.	3.8	3
462	Synthesis and Anti-HIV Evaluation of Novel 1,2,4-triazole Derivatives as Potential Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. Letters in Drug Design and Discovery, 2012, 10, 27-34.	0.7	3
463	Synthesis and Anti-HIV-1 Activity of 1-[Ï‰-(Phenoxy)Alkyl and -Alkenyl]Uracil Derivatives. Pharmaceutical Chemistry Journal, 2013, 47, 459-463.	0.8	3
464	Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127287.	2.2	3
465	Chemical space exploration of novel naphthyl-carboxamide-diarylpyrimidine derivatives with potent anti-HIV-1 activity. Bioorganic Chemistry, 2021, 111, 104905.	4.1	3
466	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. Bioorganic and Medicinal Chemistry, 2021, 42, 116239.	3.0	3
467	Synthesis and Biological Activity of N-(arylsulfonyl) Valine Hydrazones and Assistance of NMR Spectroscopy for Definitive 3D Structure. Letters in Drug Design and Discovery, 2019, 16, 974-983.	0.7	3
468	Substituted Naphthalen-1-yl-Acetic Acid Hydrazides: Synthesis, Antimicrobial Evaluation and QSAR Analysis. Medicinal Chemistry, 2013, 9, 249-274.	1.5	3

#	Article	IF	Citations
469	Synthesis and anti-HIV activity of novel 2,4-disubstituted-7-methyl-1,1,3-trioxo-2H,4H-pyrazolo[4,5-e][1,2,4]thiadiazine derivatives. Drug Discoveries and Therapeutics, 2011, 5, 279-85.	1.5	3
470	Expansion of the Sâ€“CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase. European Journal of Medicinal Chemistry, 2022, 238, 114512.	5.5	3
471	Mixed oligonucleotide analogues with an acyclic carbohydrate moiety and a N-cyanoguanidine functionality. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 1203-1206.	2.2	2
472	Amino acids derived from ornithine. International Journal of Peptide Research and Therapeutics, 1995, 2, 206-208.	0.1	2
473	Synthesis and Antiviral Evaluation of 3'-Substituted Thymidine Analogues Derived from 3'-Amino-3'-deoxythymidine. Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 541-544.	1.1	2
474	Design, synthesis, and biological evaluation of novel 5â€Alkylâ€6â€Adamantylmethylpyrimidinâ€4(3H)â€ones as <scp>HIV</scp>â€1 nonâ€nucleoside reverseâ€transcriptase inhibitors. Chemical Biology and Drug Design, 2016, 88, 380-385.	3.2	2
475	Diterpenoids from Euphorbiaceae with Potent Anti-CHIKV and Anti-HIV Activities: Are these Antiviral Properties Correlated?. Planta Medica, 2013, 79, .	1.3	2
476	Synthesis and anti-HIV Activity of New Benzimidazole, Benzothiazole and Carbohyrazide Derivatives of the anti-Inflammatory Drug Indomethacin. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2011, 66, 0953.	0.7	2
477	Z. Naturforsch. 2011, 66b, 512 - 520. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2011, 66, 0979.	0.7	2
478	Amino acid derivatives. Part 6. New analogues of the angiotensin-converting enzyme 'Captopril'. Synthesis and anti-HIV activity. Arkivoc, 2011, 2010, 242-253.	0.5	2
479	Design and Synthesis of WM5 Analogues as HIV-1 TAR RNA Binders. Open Medicinal Chemistry Journal, 2019, 13, 16-28.	2.4	2
480	Structure-Based design of [(2-Hydroxyethoxy)methyl]-6-(phenylthio)-thymine derivatives as nonnucleoside HIV-1 reverse transcriptase Inhibitors: From HEPTs to Sulfinyl-substituted HEPTs. Bioorganic Chemistry, 2022, 126, 105880.	4.1	2
481	Linker optimization of HEPT derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors: From S=O to CHOR. Chinese Chemical Letters, 2023, 34, 107663.	9.0	2
482	Human immunodeficiency virus gp120 as the primary target of action of AR177 (Zintevir). Antiviral Research, 1997, 34, A57.	4.1	1
483	4 Viral entry as the primary target of anti-HIV activity of chicoric acid and its tetra-acetyl esters. Antiviral Research, 2000, 46, A36.	4.1	1
484	Synthesis and antiviral activity of 1-substituted 3-(3,5-dimethylbenzyl)uracil against HIV-1. Nucleic Acids Symposium Series, 2004, 48, 3-4.	0.3	1
485	Introduction to the Special Issue dedicated to Prof. Erik De Clercq for reaching the Professor Emeritus status at the Katholieke Universiteit Leuven. Antiviral Research, 2006, 71, 75-76.	4.1	1
486	Non-nucleoside HIV Reverse Transcriptase Inhibitors. Part 6. Synthesis and Anti-HIV Activity of Novel 2-[(Arylcarbonylmethyl)thio]-6-arylthio DABO Analogues.. ChemInform, 2006, 37, no.	0.0	1

#	Article	IF	Citations
487	Synthesis and an Antiviral Activity Evaluation of Nucleoside 5â€²-O-(N-acyl) Phosphoramidates. Antiviral Chemistry and Chemotherapy, 2011, 21, 143-150.	0.6	1
488	New Substituted Thiazol-2-ylidene-benzamides and Their Reaction with 1-Aza-2-azoniaallene Salts. Synthesis and anti-HIV Activity. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2011, 66, 512-520.	0.7	1
489	Stereocontrolled Synthesis and Biological Evaluation of Novel Carbocyclic Nucleosides Analogues of Neplanocin F and Abacavir. Synlett, 2011, 2011, 111-115.	1.8	1
490	Selective Inhibitors of Nuclear Export (SINE) Compounds Suppress Both HIV Replication and AIDS Related Lymphoma. Blood, 2015, 126, 2751-2751.	1.4	1
491	Non-nucleoside reverse transcriptase inhibitors (Part 18): synthesis and anti-HIV activity of 4-allylamino or 4-azido substituted diaryltriazines. Yaoxue Xuebao, 2009, 44, 145-9.	0.2	1
492	The N1-(3'-Deoxythymidin-3'-yl)-N2-cyano-N3-(5'-deoxythymidin-5'-yl) Guanidine Dimeric Building Block in Automated DNA Synthesis and Mass Spectrometric Analysis of Its Integrity. Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 1037-1040.	1.1	0
493	Disulfide-containing macrolides that inhibit a late stage of the replicative cycle of human immunodeficiency virus. Antiviral Research, 1997, 34, A48.	4.1	0
494	New 1,1,3-trioxo-2H,4H-thieno[3,4-e]thiadiazine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. Antiviral Research, 1997, 34, A56.	4.1	0
495	Synthesis and anti-HIV Activity of 2,3-Diaryl-1,3-thiazolidin-4-(thi)one Derivatives.. ChemInform, 2003, 34, no.	0.0	0
496	Synthesis and anti-HIV Activity of 1-(2,6-Difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole Structurally-Related 1,2-Substituted Benzimidazoles.. ChemInform, 2003, 34, no.	0.0	0
497	Synthesis and anti-HIV Activity of 2,3-Diaryl-1,3-thiazolidin-4-ones.. ChemInform, 2003, 34, no.	0.0	0
498	Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors. Part 1. Synthesis and Structureâ€"Activity Relationship of 1-Alkoxymethyl-5-alkyl-6-naphthylmethyl Uracils as HEPT Analogues.. ChemInform, 2003, 34, no.	0.0	0
499	Synthesis of New 2,3-Diaryl-1,3-thiazolidin-4-ones and anti-HIV Agents.. ChemInform, 2004, 35, no.	0.0	0
500	5-Alkyl-2-[(aryl and alkyloxycarbonylmethyl)thio]-6-(1-naphthylmethyl) Pyrimidin-4(3H)-ones as an Unique HIV Reverse Transcriptase Inhibitors of S-DABO Series.. ChemInform, 2004, 35, no.	0.0	0
501	Aromatic Polycationic Molecules with Restricted Conformations: An Alternative Approach to Antiherpes Agents. Letters in Drug Design and Discovery, 2005, 2, 424-427.	0.7	0
502	Nonnucleoside HIV-1 Reverse-Transcriptase Inhibitors. Part 5. Synthesis and anti-HIV-1 Activity of Novel 6-Naphthylthio HEPT Analogues.. ChemInform, 2006, 37, no.	0.0	0
503	Synthesis and Antiviral Evaluation of (-)-3â€²-Methylcarbovir, (-)-3â€²-Methylabacavir, and Modified Purine Analogues. Synthesis, 2009, 2009, 290-296.	2.3	0
504	Î±â€Amino acids derived from ornithine as building blocks for peptide synthesis. Chemical Biology and Drug Design, 1997, 49, 183-189.	1.1	0

#	Article	IF	Citations
505	Inside Cover: Studies of Anti-HIV Transcription Inhibitor Quinolones: Identification of Potent N1-Vinyl Derivatives (ChemMedChem 11/2010). ChemMedChem, 2010, 5, 1798-1798.	3.2	0
506	Synthesis and anti-HIV activity of novel 2,4-disubstituted-7-methyl-1,1,3-trioxo-2H,4H-pyrazolo[4,5-e][1,2,4]thiadiazine derivatives. Drug Discoveries and Therapeutics, 2011, , .	1.5	0
507	Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Antiâ€HIVâ€1 Agents. Chemical Biology and Drug Design, 2015, 86, 333-343.	3.2	0
508	Discovery of Biphenyl-Substituted Diarylpyrimidines as New Non-Nucleoside HIV-1 Reverse Transcripttase Inhibitors. Proceedings (mdpi), 2017, 1, 220.	0.2	0
509	Antiviral Research. Satellite symposium: Clinical update on antiviral drugs. IDrugs: the Investigational Drugs Journal, 2000, 3, 760-1.	0.7	0